세계의 단백질 A 수지 시장 : 제품별, 유래별, 매트릭스 유형별, 용도별, 최종사용자별 - 예측(-2030년)

The global protein A resin market is projected to reach USD 2.0 billion by 2030 from USD 1.5 billion in 2025, at a CAGR of 6.5% during the forecast period.

Market growth is attributed to increased outsourced services through CDMOs, with major players expanding multi-plant biomanufacturing capacities across developed markets. The global monoclonal antibody (mAb) pipeline is growing, marked by high FDA approvals and new bispecific and antibody-drug conjugate launches. This has helped boost purification requirements among end users, which is expected to increase the market for protein A resin.

"Based on product, bulk resins held the largest share of the protein A resin market in 2024."

Based on products, the protein A resin market is divided into bulk resin, pre-packed columns, lab-scale columns, and others. Unlike pre-packed formats, bulk resin is the industry standard for high-volume purification processes in stainless-steel column setups. While it requires in-house packing and validation, bulk resin provides a much lower cost per cycle and per gram of purified monoclonal antibody. It is the preferred choice among end users because of its reusability. Most types can support 50 to over 200 cycles, enabling long-term production runs with minimal resin replacement. This feature directly enhances the economic efficiency and productivity goals of commercial manufacturing. All these factors make bulk resin the favored choice in the end-use industries.

"Based on matrix type, the agarose-based protein A resin segment accounted for the largest share during the forecast period."

The protein A resin market is categorized by matrix type into agarose-based, glass/silica-based, and organic polymer-based varieties. Among these, agarose-based protein A resins represent the largest market share. They are known for their improved durability, stronger mechanical properties, and higher capacity to absorb metal dopants at suitable pH levels. Recent developments in agarose-based resins include next-generation products such as Praesto CH1 and DurA Cycle A50, which offer better durability, increased binding capacity, and improved compatibility with complex antibody formats like bispecifics and fragments. These new products feature engineered ligands with enhanced alkaline resistance, enabling longer reuse and better cost efficiency.

"Based on applications, the monoclonal antibodies purification segment has acquired the largest share in 2024."

Based on applications, the protein A resin market is divided into mAb purification, Fc-fusion protein purification, and other applications. mAb purification holds the largest share in the protein A resin market mainly because of its established role in large-scale biopharmaceutical manufacturing. mAbs are the most widely produced category of biologic therapeutics, requiring large amounts of protein A resin for the primary capture steps in downstream processing. Protein A resin is preferred due to its Fc region binding specificity and compliance with regulatory standards for product purity and consistency. Moreover, a significant portion of the installed biomanufacturing capacity across pharmaceutical companies and contract manufacturing organizations is dedicated to mAb production, which naturally increases demand for protein A resin in this segment.

"Based on end users, the pharmaceutical and biopharmaceutical companies segment accounted for the largest share in 2024."

Pharmaceutical and biopharmaceutical companies account for the major share in the protein A resin market due to their role as the primary manufacturers of therapeutic proteins, particularly monoclonal antibodies (mAbs) and Fc-fusion proteins. These companies operate large-scale production facilities where protein A resin is extensively used in downstream purification processes, requiring significant resin volumes to meet commercial supply needs and regulatory compliance standards. Additionally, in-house manufacturing setups within these organizations prioritize consistent supply chains and quality control, further reinforcing direct procurement of protein A resins rather than relying solely on outsourced partners. This structural reliance on protein A resin for core biologics manufacturing activities positions pharmaceutical and biopharmaceutical companies as the dominant end-user segment in the market.

"North America is expected to hold a significant market share in the protein A resin market throughout the forecast period."

The protein A resin market includes five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America held a significant market share for protein A resin. Its dominant position is due to increased manufacturing capacity, focusing on commercial-scale and clinical trial supply production. Investment trends show that US federal and state support promotes domestic biomanufacturing for pandemic preparedness and reducing reliance on international supply chains. Small- to mid-sized biotech firms are increasingly partnering with CDMOs. These factors have helped North America secure the largest market share in 2024.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%)
• By Designation: C-level Executives (35%), Directors (25%), and Others (40%)
• By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and the Middle East & Africa (5%)

The key players profiled in the protein A resin market are Danaher Corporation (US), Repligen Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific (US), Agilent Technologies (US), GenScript (China), Bio-Rad Laboratories, Inc. (US), Orochem Technologies Inc. (US), Kaneka Corporation (Japan), Abcam Plc. (UK), Ecolab (US), and Tosoh Biosciences LLC (Japan).

Research Coverage

The research report analyzes the protein A resin market by product, matrix type, source, application, end user, and region. It explores the factors driving market growth, examines the challenges and opportunities faced by various industries, and presents details on the competitive landscape, including market leaders and small to medium-sized enterprises. Additionally, it estimates the revenue generated by different market segments across five regions and includes a micromarket analysis.

Reasons to Buy the Report

The report will help market leaders and new entrants by providing accurate revenue estimates for the protein A resin market and subsegments. It will assist stakeholders in understanding the competitive landscape, enabling them to position their businesses more effectively and develop suitable go-to-market strategies. Additionally, the report offers insights into market dynamics, including key drivers, restraints, challenges, and opportunities.

This report provides insightful data on the following pointers:

• Market Penetration: In-depth coverage of product portfolios offered by the top players in the protein A resin market.
• Product Development/Innovation: In-depth coverage of product portfolios offered by the top players in the protein A resin market.
• Market Development: Insightful data on profitable developing areas.
• Market Diversification: Details about recent developments and advancements in the protein A resin market.
• Competitive Assessment: Extensive assessment of the products, growth tactics, revenue projections, and market categories of the top competitors.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY RESEARCH
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key data from secondary sources
    • 2.1.1.3 Objectives of secondary research
  • 2.1.2 PRIMARY RESEARCH
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key supply and demand-side participants
    • 2.1.2.3 Breakdown of primary interviews
    • 2.1.2.4 Objectives of primary research
    • 2.1.2.5 Key primary insights
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Company revenue estimation
    • 2.2.1.2 Customer-based market estimation
    • 2.2.1.3 Primary interviews
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 GROWTH RATE ASSUMPTIONS
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 PROTEIN A RESIN MARKET OVERVIEW
• 4.2 ASIA PACIFIC: PROTEIN A RESIN MARKET, BY COUNTRY AND END USER
• 4.3 PROTEIN A RESIN MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Strong monoclonal antibody pipeline to drive demand
    • 5.2.1.2 Advent of continuous bioprocessing to drive adoption
    • 5.2.1.3 Increased utilization due to expansion of bispecific antibodies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High manufacturing cost and pricing pressure
    • 5.2.2.2 Issues associated with scaling up resin production
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Rising outsourcing to CDMOs
    • 5.2.3.2 Innovative therapeutic indications
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Limited resin reusability and fouling concerns
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
  • 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
• 5.5 VALUE CHAIN ANALYSIS
  • 5.5.1 RESEARCH & DEVELOPMENT
  • 5.5.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING
  • 5.5.3 DISTRIBUTION AND MARKETING & SALES
  • 5.5.4 AFTER-SALES SERVICES
• 5.6 SUPPLY CHAIN ANALYSIS
  • 5.6.1 PROMINENT COMPANIES
  • 5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
  • 5.6.3 END USERS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT & FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Recombinant protein A ligand engineering
    • 5.9.1.2 Alkaline-stable ligand development
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Automated column packing systems
    • 5.9.2.2 In-line monitoring and PAT (process analytical technology) tools
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Continuous chromatography systems
    • 5.9.3.2 Affinity membrane technology
• 5.10 PATENT ANALYSIS
  • 5.10.1 INNOVATIONS AND PATENT REGISTRATIONS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA FOR HS CODE 3504
  • 5.11.2 EXPORT DATA FOR HS CODE 3504
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 CASE STUDY ANALYSIS
  • 5.13.1 CASE STUDY 1: STRATEGIC CAPACITY EXPANSION BY PUROLITE (ECOLAB) TO STRENGTHEN SUPPLY CHAIN RESILIENCE IN PROTEIN A RESIN BUSINESS
  • 5.13.2 CASE STUDY 2: PROCESS INNOVATION BY CYTIVA TO ENHANCE REUSE CYCLES IN PROTEIN A RESINS
  • 5.13.3 CASE STUDY 3: TOSOH'S SINGLE-USE STRATEGY TO TAP INTO GROWING DEMAND FOR FLEXIBLE BIOPROCESSING
• 5.14 REGULATORY ANALYSIS
  • 5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.14.2 REGULATORY FRAMEWORK
    • 5.14.2.1 North America
      • 5.14.2.1.1 US
      • 5.14.2.1.2 Canada
    • 5.14.2.2 Europe
      • 5.14.2.2.1 UK
      • 5.14.2.2.2 Germany
      • 5.14.2.2.3 France
      • 5.14.2.2.4 Italy
      • 5.14.2.2.5 Spain
    • 5.14.2.3 Asia Pacific
      • 5.14.2.3.1 Japan
      • 5.14.2.3.2 China
      • 5.14.2.3.3 India
      • 5.14.2.3.4 Australia
    • 5.14.2.4 Latin America
      • 5.14.2.4.1 Brazil
      • 5.14.2.4.2 Mexico
    • 5.14.2.5 Middle East & Africa
      • 5.14.2.5.1 UAE
      • 5.14.2.5.2 South Africa
• 5.15 PORTER'S FIVE FORCES ANALYSIS
  • 5.15.1 THREAT OF NEW ENTRANTS
  • 5.15.2 THREAT OF SUBSTITUTES
  • 5.15.3 BARGAINING POWER OF SUPPLIERS
  • 5.15.4 BARGAINING POWER OF BUYERS
  • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.16 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.16.2 BUYING CRITERIA
• 5.17 UNMET NEEDS
• 5.18 IMPACT OF 2025 US TARIFFS-PROTEIN A RESIN MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 IMPACT ON COUNTRIES/REGIONS
    • 5.18.4.1 North America
      • 5.18.4.1.1 US
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 IMPACT ON END-USE INDUSTRIES
• 5.19 IMPACT OF AI/GEN AI ON PROTEIN A RESIN MARKET
  • 5.19.1 MARKET POTENTIAL OF AI/GEN AI IN PROTEIN A RESIN APPLICATIONS
  • 5.19.2 AI USE CASES
  • 5.19.3 KEY COMPANIES IMPLEMENTING AI/GEN AI
  • 5.19.4 FUTURE OF AI/GEN AI IN PROTEIN A RESIN ECOSYSTEM

6 PROTEIN A RESIN MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 BULK RESINS
  • 6.2.1 BULK RESINS TO HOLD LARGEST MARKET SHARE
• 6.3 PREPACKED COLUMNS
  • 6.3.1 CONSISTENCY AND LOW CROSS-CONTAMINATION RISK TO SUPPORT ADOPTION
• 6.4 LAB-SCALE COLUMNS
  • 6.4.1 FLEXIBILITY, LOW SAMPLE CONSUMPTION, AND HIGH THROUGHPUT TO DRIVE USAGE
• 6.5 OTHER PRODUCTS

7 PROTEIN A RESIN MARKET, BY SOURCE

• 7.1 INTRODUCTION
• 7.2 RECOMBINANT PROTEIN A
  • 7.2.1 COST-EFFICIENCY OF RECOMBINANT PROTEINS TO DRIVE MARKET GROWTH
• 7.3 NATURAL PROTEIN A
  • 7.3.1 ADVANTAGES OF RECOMBINANT PROTEIN A TO RESTRICT NATURALLY SOURCED COUNTERPARTS

8 PROTEIN A RESIN MARKET, BY MATRIX TYPE

• 8.1 INTRODUCTION
• 8.2 AGAROSE-BASED PROTEIN A
  • 8.2.1 AGAROSE-BASED PROTEIN A TO DOMINATE MARKET
• 8.3 GLASS/SILICA-BASED PROTEIN A
  • 8.3.1 LOW PH TOLERANCE OF SILICA-BASED RESINS TO LIMIT MARKET GROWTH
• 8.4 ORGANIC POLYMER-BASED PROTEIN A
  • 8.4.1 INCREASING POPULARITY OF ORGANIC POLYMERS TO DRIVE MARKET GROWTH

9 PROTEIN A RESIN MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 MONOCLONAL ANTIBODY PURIFICATION
  • 9.2.1 GROWING DEMAND, RAPID EXPANSION OF APPLICATIONS, AND INCREASING APPROVALS TO ENSURE LARGEST SHARE
• 9.3 FC-FUSION PROTEIN PURIFICATION
  • 9.3.1 INNOVATION AND PATENTED PUBLICATIONS TO DRIVE MARKET
• 9.4 OTHER APPLICATIONS

10 PROTEIN A RESIN MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  • 10.2.1 EXTENSIVE USE IN BIOLOGICAL DRUG PRODUCTION TO ENSURE STRONG DEMAND
• 10.3 CROS & CDMOS
  • 10.3.1 EXPANSION OF BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET GROWTH
• 10.4 ACADEMIC & RESEARCH INSTITUTES
  • 10.4.1 INCREASING R&D IN DRUG DISCOVERY TO DRIVE USE OF PROTEIN A RESINS
• 10.5 OTHER END USERS

11 PROTEIN A RESIN MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Expansion in biomanufacturing and domestic capacity to drive market
  • 11.2.3 CANADA
    • 11.2.3.1 Policy-led capacity build and CDMO growth to drive the market
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Increased capital expenditure from manufacturers to drive market
  • 11.3.3 UK
    • 11.3.3.1 Government policies and public-private partnerships to drive market
  • 11.3.4 FRANCE
    • 11.3.4.1 CDMO capacity expansion and public programs to drive market growth
  • 11.3.5 ITALY
    • 11.3.5.1 Increased Cap Ex from major end-user categories to grow the demand for protein A resin
  • 11.3.6 SPAIN
    • 11.3.6.1 Increased CDMO and CRO likely to grow demand for protein A resin
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 CDMO capacity expansions, policy backing, and CDMO investment to propel market
  • 11.4.3 CHINA
    • 11.4.3.1 Robust biopharmaceutical expansion to grow demand
  • 11.4.4 INDIA
    • 11.4.4.1 Growth of pharma and biotech industries to drive demand for protein A resins
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Increasing demand for protein-based therapeutics to drive growth
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Developments in biopharmaceutical sector to drive market growth
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Biomanufacturing emphasis and public-private partnerships to catalyze demand
  • 11.5.3 MEXICO
    • 11.5.3.1 Supportive government initiatives to grow demand for protein A resin
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Favorable government policies to propel market growth
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PROTEIN A RESIN MARKET
• 12.3 REVENUE ANALYSIS OF KEY PLAYERS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.4.1 MARKET RANKING OF KEY PLAYERS, 2024
• 12.5 COMPANY VALUATION & FINANCIAL METRICS
• 12.6 BRAND/PRODUCT COMPARISON
• 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.7.1 STARS
  • 12.7.2 PERVASIVE PLAYERS
  • 12.7.3 EMERGING LEADERS
  • 12.7.4 PARTICIPANTS
  • 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.7.5.1 Company footprint
    • 12.7.5.2 Region footprint
    • 12.7.5.3 Product footprint
    • 12.7.5.4 Matrix type footprint
    • 12.7.5.5 Application footprint
    • 12.7.5.6 End-user footprint
• 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.8.1 PROGRESSIVE COMPANIES
  • 12.8.2 RESPONSIVE COMPANIES
  • 12.8.3 DYNAMIC COMPANIES
  • 12.8.4 STARTING BLOCKS
  • 12.8.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2024
    • 12.8.5.1 Detailed list of key startups/SMEs
    • 12.8.5.2 Competitive benchmarking of key startups/SMEs
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES & APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 DANAHER
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 THERMO FISHER SCIENTIFIC INC.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Deals
      • 13.1.2.3.2 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 AGILENT TECHNOLOGIES, INC.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Deals
      • 13.1.3.3.2 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 BIO-RAD LABORATORIES, INC
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
  • 13.1.5 MERCK KGAA
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Expansions
      • 13.1.5.3.2 Other developments
  • 13.1.6 REPLIGEN CORPORATION
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Deals
    • 13.1.6.4 MnM view
      • 13.1.6.4.1 Right to win
      • 13.1.6.4.2 Strategic choices
      • 13.1.6.4.3 Weaknesses and competitive threats
  • 13.1.7 TOSOH BIOSCIENCE
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Expansions
  • 13.1.8 ECOLAB INC.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product launches
      • 13.1.8.3.2 Deals
      • 13.1.8.3.3 Expansions
    • 13.1.8.4 MnM view
      • 13.1.8.4.1 Key strengths
      • 13.1.8.4.2 Strategic choices
      • 13.1.8.4.3 Weaknesses & competitive threats
  • 13.1.9 NOVASEP HOLDING
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
  • 13.1.10 AVANTOR, INC.
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
  • 13.1.11 OROCHEM TECHNOLOGIES, INC.
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
  • 13.1.12 KANEKA CORPORATION
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
  • 13.1.13 JSR CORPORATION
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
  • 13.1.14 GENSCRIPT
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 BIO-WORKS
  • 13.2.2 GENO TECHNOLOGY, INC.
  • 13.2.3 PROMEGA CORPORATION
  • 13.2.4 SUZHOU NANOMICRO TECHNOLOGY CO., LTD.
  • 13.2.5 TRANSGEN BIOTECH CO., LTD
  • 13.2.6 RESYN BIOSCIENCES (PTY) LTD
  • 13.2.7 BIOTOOLOMICS LTD.
  • 13.2.8 CALIBRE SCIENTIFIC (PROTEIN ARK)
  • 13.2.9 SUNRESIN NEW MATERIALS CO., LTD.
  • 13.2.10 BEAVER

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS